+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 552 Pages
  • April 2022
  • Region: Global
  • Roots Analysis
  • ID: 5578957
The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. The project was undertaken to understand the concept of core human microbiome and its compatibility with the host physiology. Further, with the significant advancements in the sequencing methods and analytical techniques, and 40% increase in the non-HMP investments, several microbiome-related studies have been conducted. Research insights generated from the HMP and other studies throw light on the role of gut microbiota in governing the overall health / well-being of an individual, and the pathogenesis of several diseases due to the alteration in the composition of resident gut microbiota. Specifically, the studies suggest that dysbiosis (imbalance of gut bacteria) leads to the development of several chronic conditions, including Clostridium difficile infections (CDIs), Crohn’s disease, irritable bowel disease, ulcerative colitis and diabetes. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Manipulation of bacteria in the gut emerges to be a potential tool in the treatment of various medical conditions and associated diseases. The ongoing research efforts, focused on targeting and modulating microbiome, have led to the development of treatment options for more than 25 indications. In addition, probiotic therapies with live biotherapeutic products (microbes) are considered to be the most advanced microbiome-based therapies for restoring bacterial symbiosis. 

At present, fecal microbiota transplantation (FMT) involving the transfer of complete microbial community from a healthy donor’s feces to recipient via oral (in form of a capsule) or rectal (enema and colonoscopy) is the only FDA-approved microbiome therapy, for the treatment of recurrent CDI. However, several players are engaged in developing prescription drugs modulating human microbiome for the treatment of various gastrointestinal and non-gastrointestinal disorders as well. Further, a number of microbiome diagnostic and screening / profiling tests are commercially available for the detection of different microbiome-related diseases. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in this domain. Driven by increasing prevalence of disease indications, promising therapeutic potential of microbiome-based therapies, encouraging clinical trial results and financial support from the investors, the human microbiome therapeutics and diagnostics market is likely to witness substantial growth in the mid to long-term.


Scope of the Report


The ‘The Human Microbiome Market (4th Edition), 2022-2035: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapies: Distribution by Type of Molecule (Small Molecule and Biologic), Type of Product (Probiotic Drugs and Other Drugs), Target Indication (Bacterial Vaginosis, Diabetes, Gingivitis, Irritable Bowel Syndrome, Leaky Gut Syndrome, Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, recurrent CDI, Trichomoniasis and Vaginal Candidiasis), Therapeutic Areas (Dental Disorders, Digestive and Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Rare Disorders and Others)Route of Administration (Oral and Rectal), Supply Channels (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based therapeutics, diagnostics and FMTs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. 


In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of microbiome therapeutics, providing information on preclinical and clinical drugs along with information on clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, prescription drug and vaccine), target indication(s), therapeutic area(s), route of administration, type of drug formulation, type of therapy (monotherapy and combination therapy), combination drug (in case of combination therapies), dosing frequency (reported for clinical candidates only), and special drug designations (if any). In addition, the chapter provides details on the companies engaged in the development of microbiome therapeutics, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of microbiome therapeutics (which are presently in phase III clinical trials); each profile features a brief overview of the company, its financial information (if available), microbiome-based drug portfolio, information on clinical trial (featuring, current status of development and phase III clinical trial information) and an informed future outlook. In addition, the chapter also features profiles of the players engaged in more than six therapeutic programs, along with a company overview, financial information (if available), drug portfolio and an informed future outlook.
  • A detailed analysis of completed and ongoing clinical trials of various microbiome therapeutics, based on different parameters, such as trial status, trial registration year, trial status, year-wise trend of completed and recruiting trials, study design, number of patients enrolled. In addition, the chapter highlights, the age group of the patients enrolled, type of sponsor / collaborator, active industry and non-industry players and location of the trials.
  • An analysis on the various types of diagnostic and screening / profiling tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with detailed review of the current market landscape of microbiome diagnostic and screening / profiling tests, including the information on stage of development (commercialized and under development), type of sample analyzed (blood, feces, saliva and vaginal swab), type of screening technique (gene sequencing, PCR, microarray, ELISA, DNA analysis, drug metabolites and others) target indication(s), key therapeutic area(s) and purpose of diagnosis. The chapter also features information on the diagnostics and screening / profiling test providers(s) along with information on their year of establishment, company size and location of headquarters. 
  • Elaborate profiles of key players engaged in the development of microbiome diagnostics and screening / profiling tests. Each profile features a brief overview of the company, its financial information (if available), diagnostic or screening / profiling test portfolio, recent developments and an informed future outlook.
  • A review of the historical evolution and other relevant aspects of FMT, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with detailed assessment of the current market landscape of FMT, providing information on various parameters of FMT such as, the status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration. In addition, the chapter includes information on FMT provider(s), along with information on their year of establishment, company size and location of headquarters. 
  • A detailed analysis of completed and ongoing clinical trials of FMT, based on different parameters, such as trial status, trial registration year, trial phase, year-wise trend of completed and recruiting trials, study design, number of patients enrolled. In addition, the chapter highlights age category of the patients enrolled, type of sponsor / collaborator, active industry and non-industry players and location of the trials. Furthermore, the chapter also features information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
  • A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
  • An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
  • An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s).
  • An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
  • An analysis of the partnerships that have been established since 2017, covering various parameters such as, research and development, clinical trials agreement, merger / acquisition, product development and commercialization agreement and product development and manufacturing agreement of the companies focused on developing microbiome-based therapeutics, diagnostics and FMTs.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
  • An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, type of product manufactured and type of formulation. In addition, the chapter highlights key consideration for selecting a CMO / CRO partner.
  • An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade. The chapter also features a list of companies offering big data-related services / tools to support microbiome research, and brief profiles of some of the popular companies that are engaged in this field of research.
  • A case study on various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over the counter (OTC) products that are being used as dietary supplements.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends of the sales, of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs. The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across type of molecule (small molecule and biologics), type of product (probiotic and other drug), target indication (graft versus host disease, necrotizing enterocolitis, primary hyperoxaluria and recurrent CDI ), therapeutic area (digestive and gastrointestinal disorders, infectious diseases and rare disorders), route of administration (oral and rectal), key geographical regions (North America, Europe, Asia-Pacific and rest of the world), leading drug developers, and leading therapeutic products. In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across target indications (bacterial vaginosis, diabetes, gingivitis, irritable bowel syndrome, leaky gut syndrome, trichomoniasis and vaginal candidiasis), therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and others), supply channel (hospital, retail , and online pharmacies), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 
 
The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain.


The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

  • Lee Jones (President and Chief Executive Officer, Rebiotix)
  • Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
  • Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)
  • Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)
  • James Burges (Co-founder and Vice President of Innovation, Finch Therapeutics)
  • JP Benya (Vice President, Operations, Flame Biosciences)
  • Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)
  • Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics) 
  • Mark Heiman (Chief Scientific Officer and Vice President, Research, Scioto Biosciences) 
  • Alexander Segal (Founder, Stealth Startup)
  • Assaf Oron (Chief Business Officer, BiomX)
  • Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra)
  • Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
  • Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
  • Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)
  • Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)


Key Questions Answered

  • Who are the leading players engaged in the development of microbiome therapeutics?
  • Which are the key drugs being developed across various stages of development?
  • Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?
  • Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors active in the field of human microbiome therapeutics and diagnostics?
  • What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
  • What is the role of various start-ups engaged in the developing human microbiome therapeutics?
  • Which are the most commonly targeted therapeutic indications for microbiome therapeutics are being developed?
  • What are the various steps involved in the manufacturing of microbiome therapeutics and what are the key considerations for selecting a CMO / CRO?
  • What are the various algorithms / tools used to analyze data generated from microbiome research?
  • How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?
  • What are the various non-pharma applications of microbiome products?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.2.1. Discovery of the Human Microbiome
3.2.2. Functions of the Human Microbiome
3.3. Overview of Gut Flora
3.3.1. Role of Gut Flora in Human Health
3.3.2. Factors Affecting Gut Flora
3.3.2.1. Antibiotic Consumption
3.3.2.2. Age and Pregnancy
3.3.2.2.1. Mode of Childbirth
3.3.2.2.2. Type of Feeding
3.3.2.2.3. Antibiotic Consumption by Mother
3.3.2.3. Stress-related Factors
3.3.2.4. Dietary Factors
3.3.2.5. Impact of Lifestyle
3.4. The Microbiome and Associated Diseases
3.4.1. Cancer
3.4.2. Inflammatory Bowel Disease (IBD)
3.4.3. Obesity
3.4.4. Parkinson’s Disease
3.4.5. Type 2 Diabetes
3.4.6. Other Disease Indications
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes
3.7. Microbiome Therapeutics
3.7.1. Probiotics
3.7.1.1. Beneficial Bacterial Strains
3.7.1.1.1. Lactobacilli
3.7.1.1.2. Bifidobacteria
3.7.1.1.3. Others
3.7.1.2. Key Therapeutic Areas
3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
3.7.1.2.2. Bacterial Vaginosis
3.7.1.2.3. High Blood Pressure
3.7.1.2.4. Hypercholesterolemia
3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
3.7.1.2.6. Inflammatory Bowel Disease (IBD)
3.7.1.2.7. Lactose Intolerance
3.7.1.2.8. Vitamin Production
3.7.1.2.9. Weight Management
3.7.1.3. Side Effects of Probiotics
3.7.2. Prebiotics
3.7.2.1. Sources of Prebiotics
3.7.2.2. Types of Prebiotics
3.7.2.2.1. Fructo-Oligosaccharides (FOS)
3.7.2.2.2. Galacto-Oligosaccharides (GOS)
3.7.2.2.3. Inulin
3.7.2.3. Key Therapeutic Areas
3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
3.7.2.3.2. Constipation
3.7.2.3.3. Gastrointestinal Diseases
3.7.2.3.4. Dysbiosis
3.7.2.4. Side Effects of Prebiotics
3.8. The Human Microbiome Project (HMP)
3.8.1. Project Approach
3.8.2. Project Initiatives
3.8.3. Project Achievements
3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
3.11. Future Perspectives
4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Phase of Development and Type of Molecule
4.2.4. Analysis by Type of Biologic
4.2.5. Analysis by Type of Product
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Type of Formulation
4.2.10. Analysis by Dose Frequency
4.2.11. Analysis by Type of Therapy
4.2.12. Analysis by Combination Drug
4.3. Microbiome Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Phase of Development and Type of Molecule
4.3.4. Analysis by Type of Biologic
4.3.5. Analysis by Type of Product
4.3.6. Analysis by Target Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Route of Administration
4.4. Microbiome Therapeutics: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Leading Drug Developers: Analysis by Number of Therapeutic Programs
5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
5.3. Finch Therapeutics
5.3.1. Company Overview
5.3.2. Microbiome-Based Product Portfolio
5.3.2.1. CP101
5.3.2.1.1. Drug Overview
5.3.2.1.2. Current Status of Development
5.3.2.1.3. Clinical Studies
5.3.3. Recent Developments and Future Outlook
5.4. Infant Bacterial Therapeutics
5.4.1. Company Overview
5.4.2. Microbiome-Based Product Portfolio
5.4.2.1. IBP-9414
5.4.2.1.1. Drug Overview
5.4.2.1.2. Current Status of Development
5.4.2.1.3. Clinical Studies
5.4.3. Recent Developments and Future Outlook
5.5. MaaT Pharma
5.5.1. Company Overview
5.5.2. Microbiome-Based Product Portfolio
5.5.2.1. MaaT013
5.5.2.1.1. Drug Overview
5.5.2.1.2. Current Status of Development
5.5.2.1.3. Clinical Studies
5.5.3. Recent Developments and Future Outlook
5.6.1 OxThera
5.6.1. Company Overview
5.6.2. Microbiome-Based Product Portfolio
5.6.2.1. Oxabact
5.6.2.1.1. Drug Overview
5.6.2.1.2. Current Status of Development
5.6.2.1.3. Clinical Studies
5.6.3. Recent Developments and Future Outlook
5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Microbiome-Based Product Portfolio
5.7.3.1. RBX2660
5.7.3.1.1. Drug Overview
5.7.3.1.2. Current Status of Development
5.7.3.1.3. Clinical Studies
5.7.4. Recent Developments and Future Outlook
5.8. Seres Therapeutics
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Microbiome-Based Product Portfolio
5.8.3.1. SER-109
5.8.3.1.1. Drug Overview
5.8.3.1.2. Current Status of Development
5.8.3.1.3. Clinical Studies
5.8.3.1.4. Clinical Trial End-Point Analysis
5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
5.10. 4D Pharma
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Microbiome-based Drug Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Biosortia Pharmaceuticals
5.11.1. Company Overview
5.11.2 Microbiome-based Drug Portfolio
5.11.3. Recent Developments and Future Outlook
5.12. Qu Biologics
5.12.1. Company Overview
5.12.2. Microbiome-based Drug Portfolio
5.12.3. Recent Developments and Future Outlook
5.13. Servatus
5.13.1 Company Overview
5.13.2. Microbiome-based Drug Portfolio
5.13.3. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS
6.1. Chapter Overview
6.2. Human Microbiome Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Type of Study
6.2.4. Analysis by Trial Phase and Trial Status
6.2.5. Year-wise Trend of Completed and Recruiting Trials
6.2.6. Analysis by Study Design
6.2.7. Analysis by Patient Enrollment
6.2.8. Analysis by Age Category
6.2.9. Analysis by Type of Sponsor / Collaborator
6.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.2.12. Analysis by Trial Location
6.2.13. Analysis by Trial Status and Geography
7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
7.3.1. Analysis by Stage of Development
7.3.2. Analysis by Type of Test
7.3.3. Analysis by Stage of Development and Type of Test
7.3.4. Analysis by Type of Sample Analyzed
7.3.5. Analysis by Type of Screening Technique
7.3.6. Analysis by Target Indication
7.3.7. Analysis by Therapeutic Area
7.3.8. Analysis by Purpose of Test
7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
7.4.1. Analysis by Year of Establishment
7.4.2. Analysis by Company Size
7.4.3. Analysis by Location of Headquarters
7.4.4. Analysis by Company Size and Location of Headquarters
7.4.5. Most Active Microbiome Test Providers: Analysis by Number of Microbiome Tests
8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES
8.1. Chapter Overview
8.2. Shoreline Biome
8.2.1. Company Overview
8.2.2. Microbiome Test Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. DNA Genotek
8.3.1. Company Overview
8.3.2. Microbiome Test Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. Invivo Healthcare
8.4.1. Company Overview
8.4.2. Microbiome Test Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. GoodGut
8.5.1. Company Overview
8.5.2. Microbiome Test Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. BiomeDx
8.6.1. Company Overview
8.6.2. Microbiome Test Portfolio
8.6.3. Recent Developments and Future Outlook
9. FECAL MICROBIOTA THERAPY (FMT)
9.1. Chapter Overview
9.2. Introduction to Fecal Microbiota Therapy
9.3. Historical Overview
9.4. Fecal Microbiota Therapy: Procedure and Clinical Relevance
9.4.1. Donor Selection
9.4.2. Administration Procedure
9.4.3. Routes of Administration
9.4.4. Consequences and Adverse Events
9.4.5. Clinical Guidelines Associated with Fecal Microbiota Therapy
9.5. Regulatory Guidelines Related to Fecal Microbiota Therapy
9.6. Insurance Coverage for Fecal Microbota Therapy
9.7. Fecal Microbiota Therapy: Marketed and Development Pipeline
9.7.1. Analysis by Application Area
9.7.2. Analysis by Status of Development
9.7.3. Analysis by Target Indication
9.7.1.2. Analysis by Therapeutic Area
9.7.1.3. Analysis by Route of Administration
9.8. Fecal Microbiota Therapy: List of Developers
9.8.1. Analysis by Year of Establishment
9.8.2. Analysis by Company Size
9.8.3. Analysis by Location of Headquarters
9.9. Stool Banks
9.9.1. Introduction to Stool Banks
9.9.2. List of Stool Banks
9.9.3. Profiles of Prominent Stool Banks
9.9.3.1. AdvancingBio
9.9.3.1.1. Overview
9.9.3.1.2. Fecal Microbiota Preparation
9.9.3.2. Asia Microbiota bank
9.9.3.2.1. Overview
9.9.3.2.2. Fecal Microbiota Preparation
9.9.3.3. Enterobiotix
9.9.3.3.1. Overview
9.9.3.3.2. Fecal Microbiota Preparation
9.9.3.4. Flora Medicine
9.9.3.4.1. Overview
9.9.3.4.2. Fecal Microbiota Preparation
9.9.3.5. OpenBiome
9.9.3.5.1. Overview
9.9.3.5.2. Fecal Microbiota Preparation
10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY
10.1. Chapter Overview
10.2. List of Clinical Trials
10.2.1. Analysis by Trial Status
10.2.2. Analysis by Trial Registration Year
10.2.3. Analysis by Trial Registration Year and Type of Study
10.2.4. Analysis by Trial Phase and Trial Status
10.2.5. Year-wise Trend of Completed and Recruiting Trials
10.2.6. Analysis by Study Design
10.2.7. Analysis by Patient Enrollment
10.2.8. Analysis by Age Category
10.2.9. Analysis by Type of Sponsor / Collaborator
10.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
10.2.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
10.2.12. Analysis by Trial Location
10.2.13. Analysis by Trial Status and Geography
11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
11.1. Chapter Overview
11.2. AC Matrix: An Overview
11.2.1. Strong Business Units
11.2.2. Average Business Units
11.2.3. Weak Business Units
11.3. AC Matrix: Analytical Methodology
11.4. AC Matrix: Plotting the Information
11.5. AC Matrix: Analyzing the Data
11.5.1. Strong Business Units
11.5.2. Average Business Units
11.5.3. Weak Business Units
11.6. Concluding Remarks
12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Initiatives of Big Pharma Players
12.3.1. Analysis by Portfolio Diversity
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Molecule
12.3.4. Analysis by Type of Therapy
12.3.5. Analysis by Diversity of Therapeutic Areas
12.4. Benchmarking Analysis of Big Pharma Players
12.4.1. Spider Web Analysis: Company A
12.4.2. Spider Web Analysis: Company B
12.4.3. Spider Web Analysis: Company C
12.4.4. Spider Web Analysis: Company D
12.4.5. Spider Web Analysis: Company E
12.4.6. Spider Web Analysis: Company F
12.4.7. Spider Web Analysis: Company G
12.4.8. Spider Web Analysis: Company H
12.4.9. Spider Web Analysis: Company I
12.4.10. Spider Web Analysis: Company J
12.4.11. Spider Web Analysis: Company K
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Benchmarking of Start-ups
13.3.1. Analysis by Portfolio Diversity
13.3.2. Analysis by Phase of Development
13.3.3. Analysis by Diversity in Therapeutic Areas
13.3.4. Analysis by Funding Amount
13.3.5. Analysis by Number of Investors
13.3.6. Analysis by Type of Funding
13.3.7. Analysis by Partnership Activity
13.3.8. Analysis by Patent Portfolio
13.3.9. Start-up Health Indexing: Roots Analysis Perspective
14. KEY THERAPEUTIC AREAS
14.1. Chapter Overview
14.2. Metabolic Disorders
14.2.1. Diabetes
14.2.1.1. Disease Description
14.2.1.2. Associated Health Risks / Complications
14.2.1.3. Epidemiology
14.2.1.4. Disease Diagnosis
14.2.1.5. Current Treatment Options
14.2.1.5.1. Insulin Therapies
14.2.1.5.2. Non-Insulin Therapies
14.2.1.6. Side Effects of Current Treatment Options
14.2.1.7. Microbiome Therapeutics for Diabetes
14.2.2. Lactose Intolerance
14.2.2.1. Disease Description
14.2.2.2. Epidemiology
14.2.2.3. Current Treatment Options
14.2.2.4. Microbiome Therapeutics for Lactose Intolerance
14.2.3. Nonalcoholic Steatohepatitis (NASH)
14.2.3.1. Disease Description
14.2.3.2. Epidemiology
14.2.3.3. Current Treatment Options
14.2.3.4. Microbiome Therapeutics for NASH
14.2.4. Primary Hyperoxaluria
14.2.4.1. Disease Description
14.2.4.2. Epidemiology
14.2.4.3. Current Treatment Options
14.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
14.2.5. Obesity
14.2.5.1. Disease Description
14.2.5.2. Epidemiology
14.2.5.3. Current Treatment Options
14.2.5.4. Side Effects of Current Treatment Options
14.2.5.5. Microbiome Therapeutics for Obesity
14.3. Digestive and Gastrointestinal Disorders
14.3.1. Crohn’s Disease
14.3.1.1. Disease Description
14.3.1.2. Epidemiology
14.3.1.3. Current Treatment Options
14.3.1.4. Side Effects of Current Treatment Options
14.3.1.5. Microbiome Therapeutics for Crohn’s Disease
14.3.2. Irritable Bowel Syndrome (IBS)
14.3.2.1. Disease Description
14.3.2.2. Epidemiology
14.3.2.3. Current Treatment Options
14.3.2.4. Microbiome Therapeutics for IBS
14.3.3. Ulcerative Colitis
14.3.3.1. Disease Description
14.3.3.2. Epidemiology
14.3.3.3. Current Treatment Options
14.3.3.4. Side Effects of Current Treatment Options
14.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
14.4. Oncological Indications
14.4.1. Colorectal Cancer
14.4.1.1. Disease Description
14.4.1.2. Epidemiology
14.4.1.3. Current Treatment Options
14.4.1.4. Side Effects of Current Treatments
14.4.1.5. Microbiome Therapeutics for Colorectal Cancer
14.4.2. Lung Cancer
14.4.2.1. Disease Description
14.4.2.2. Epidemiology
14.4.2.3. Current Treatment Options
14.4.2.4. Side Effects of Current Treatment Options
14.4.2.5. Microbiome Therapeutics for Lung Cancer
14.5. Dermatological Disorders
14.5.1. Acne Vulgaris
14.5.1.1. Disease Description
14.5.1.2. Epidemiology
14.5.1.3. Current Treatment Options
14.5.1.4. Side Effects of Current Treatment Options
14.5.1.5. Microbiome Therapeutics for Acne Vulgaris
14.6. Infectious Diseases
14.6.1. Clostridium Difficile Infections (CDIs)
14.6.1.1. Disease Description
14.6.1.2. Epidemiology
14.6.1.3. Disease Diagnosis
14.6.1.4. Current Treatment Options
14.6.1.5. Side Effects of Current Treatment Options
14.6.1.6. Microbiome Therapeutics for CDI
14.6.2. Bacterial Vaginosis
14.6.2.1. Disease Description
14.6.2.2. Epidemiology
14.6.2.3. Current Treatment Options
14.6.2.4. Side Effects of Current Treatment Options
14.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Human Microbiome: List of Partnerships and Collaborations
15.4. Analysis by Year of Partnership
15.5. Analysis by Type of Partnership
15.6. Analysis by Year and Type of Partnership
15.7. Analysis by Type of Product
15.8. Analysis by Target Indication
15.9. Analysis by Therapeutic Area
15.10. Analysis by Type of Company
15.11. Analysis by Type of Partner
15.12. Most Active Players: Analysis by Number of Partnerships
15.13. Intercontinental and Intracontinental Agreements
16. FUNDING AND INVESTMENT ANALYSIS
16.1. Chapter Overview
16.2. Types of Funding
16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
16.3.1. Analysis by Year of Investment
16.3.2. Analysis by Amount Invested
16.3.3. Analysis by Type of Funding
16.3.4. Analysis by Type of Company
16.3.5. Analysis by Purpose of Funding
16.3.6. Analysis by Type of Product
16.3.7. Analysis by Target Indication
16.3.9. Analysis by Therapeutic Area
16.3.10. Analysis by Geography
16.3.11. Most Active Players: Analysis by Number of Instances
16.3.12. Most Active Players: Analysis by Amount Invested
16.3.12. Most Active Investors: Analysis by Number of Instances
16.3.13 Funding and Investment Summary
17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS
17.1. Chapter Overview
17.2. Manufacturing Microbiome Therapeutics
17.2.1. Key Steps Involved
17.2.2. Associated Challenges
17.2.3. Growing Demand for Contract Manufacturing Services
17.2.4. Contract Manufacturing Organizations (CMOs)
17.2.4.1. Introduction to Contract Manufacturing
17.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
17.2.5.1. Analysis by Year of Establishment
17.2.5.2. Analysis by Company Size
17.2.5.3. Analysis by Location of Headquarters
17.2.5.4. Analysis by Scale of Operation
17.2.5.5. Analysis by Type of Product Manufactured
17.2.5.6. Analysis by Type of Formulation
17.2.5.7. Analysis by Scale of Operation and Type of Formulation
17.3. Key Considerations for Selecting a CMO / CRO Partner
18. BIG DATA AND MICROBIOME THERAPEUTICS
18.1. Chapter Overview
18.2. Introduction to Big Data
18.3. Internet of Things (IoT)
18.4. Growing Interest in Big Data: Google Trends Analysis
18.5. Key Application Areas
18.6. Big Data in Microbiome Research
18.6.1. Microbiome Data and Personalized Medicine
18.6.2. Microbiome-related Data Management Challenges
18.6.3. National Microbiome Data Center
18.7. Big Data Services for Microbiome Research: List of Companies
18.8. Big Data Services for Microbiome Research: Profiles of Key Players
18.8.1. Human Longevity
18.8.1.1. Company Overview
18.8.1.2. Technology and Service Portfolio
18.8.1.3. Recent Developments and Future Outlook
18.8.2. Resilient Biotics
18.8.2.1. Company Overview
18.8.2.2. Technology and Service Portfolio
18.8.2.3. Recent Developments and Future Outlook
18.8.3. Resphera Biosciences
18.8.3.1. Company Overview
18.8.3.2. Technology and Service Portfolio
18.8.3.3. Recent Developments and Future Outlook
19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions
19.3. Forecast Methodology
19.4. Global Microbiome Therapeutics Market, 2022-2035
19.4.1. Microbiome Therapeutics Market: Distribution by Type of Product 2022-2035
19.4.1.1. Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035
19.4.1.2. Microbiome Therapeutics Market for Other Drugs, 2022-2035
19.4.2. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022-2035
19.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2022-2035
19.4.2.2. Microbiome Therapeutics Market for Biologics, 2022-2035
19.4.3. Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022-2035
19.4.3.1. Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035
19.4.3.2. Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035
19.4.3.3. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035
19.4.3.4. Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035
19.4.4. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022-2035
19.4.4.1. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035
19.4.4.2. Microbiome Therapeutics Market for Infectious Diseases, 2022-2035
19.4.4.3. Microbiome Therapeutics Market for Rare Disorders, 2022-2035
19.4.5. Microbiome Therapeutics Market: Route of Administration, 2022-2035
19.4.5.1. Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035
19.4.5.2. Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035
19.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035
19.4.6.1. Microbiome Therapeutics Market in North America, 2022-2035
19.4.6.2. Microbiome Therapeutics Market in Europe, 2022-2035
19.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035
19.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035
19.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035
19.5.1. Drug-wise Sales Forecast
19.5.1.1. CP101 (Finch Therapeutics)
19.5.1.2. Sales Forecast, 2022-2035 (USD Million)
19.5.1.3. Net Present Value (USD Million)
19.5.1.4. Value Creation Analysis
19.5.2. IBP-9414 (Infant Bacterial Therapeutics)
19.5.2.1. Sales Forecast, 2022-2035 (USD Million)
19.5.2.2. Net Present Value (USD Million)
19.5.2.3. Value Creation Analysis
19.5.3. MaaT013 (MaaT Pharma)
19.5.3.1. Sales Forecast,2022-2035 (USD Million)
19.5.3.2. Net Present Value (USD Million)
19.5.3.3. Value Creation Analysis
19.5.4. Oxabact (OxThera)
19.5.4.1. Sales Forecast, 2022-2035 (USD Million)
19.5.4.2. Net Present Value (USD Million)
19.5.4.3. Value Creation Analysis
19.5.5. RBX2660 (Rebiotix)
19.5.5.1. Sales Forecast, 2022-2035 (USD Million)
19.5.5.2. Net Present Value (USD Million)
19.5.5.3. Value Creation Analysis
19.5.6. SER-109 (Seres Therapeutics)
19.5.6.1. Sales Forecast (USD Million)
19.5.6.2. Net Present Value (USD Million)
19.5.6.3. Value Creation Analysis
20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions
20.3 Forecast Methodology
20.4. Global Microbiome Diagnostics Market, 2022-2035
20.4.1. Global Microbiome Diagnostics Market, 2022-2035 (By Value)
20.4.2. Global Microbiome Diagnostics Market, 2022-2035 (By Volume)
20.5. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035
20.5.1. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (By Value)
20.5.1.1. Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (By Value)
20.5.1.2. Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (By Value)
20.5.1.3. Microbiome Diagnostics Market for Diabetes, 2022-2035 (By Value)
20.5.1.4. Microbiome Diagnostics Market for IBS, 2022-2035 (By Value)
20.5.1.5. Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (By Value)
20.5.1.6. Microbiome Diagnostics Market for NASH, 2022-2035 (By Value)
20.5.1.7. Microbiome Diagnostics Market for Obesity, 2022-2035 (By Value)
20.5.1.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (By Value)
20.5.2. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (By Volume)
20.5.2.1. Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (By Volume)
20.5.2.2. Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (By Volume)
20.5.2.3. Microbiome Diagnostics Market for Diabetes, 2022-2035 (By Volume)
20.5.2.4. Microbiome Diagnostics Market for IBS, 2022-2035 (By Volume)
20.5.2.5. Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (By Volume)
20.5.2.6. Microbiome Diagnostics Market for NASH, 2022-2035 (By Volume)
20.5.2.7. Microbiome Diagnostics Market for Obesity, 2022-2035 (By Volume)
20.5.2.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (By Volume)
20.6. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035
20.6.1. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035 (By Value)
20.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (By Value)
20.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (By Value)
20.6.1.3. Microbiome Diagnostics Market for Oncology, 2022-2035 (By Value)
20.6.2. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035 (By Volume)
20.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (By Volume)
20.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (By Volume)
20.6.2.3. Microbiome Diagnostics Market for Oncology, 2022-2035 (By Volume)
20.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035
20.7.1. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (By Value)
20.7.1.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (By Value)
20.7.1.2. Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (By Value)
20.7.1.3. Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (By Value)
20.7.2. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (By Volume)
20.7.2.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (By Volume)
20.7.2.2. Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (By Volume)
20.7.2.3. Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (By Volume)
20.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035
20.8.1. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (By Value)
20.8.1.1. Microbiome Diagnostics Market in North America, 2022-2035 (By Value)
20.8.1.2. Microbiome Diagnostics Market in Europe, 2022-2035 (By Value)
20.8.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (By Value)
20.8.2. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (By Volume)
20.8.2.1. Microbiome Diagnostics Market in North America, 2022-2035 (By Volume)
20.8.2.2. Microbiome Diagnostics Market in Europe, 2022-2035 (By Volume)
20.8.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (By Volume)
21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Key Assumptions
21.3. Forecast Methodology
21.4. Overall FMT Market, 2022-2035
21.4.1. Overall FMT Market, 2022-2035 (By Value)
21.4.2. Overall FMT Market, 2022-2035 (By Volume)
21.5. Overall Microbiome Market by Product Offerings, 2022-2035
22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES
22.1. Chapter Overview
22.2. List of Microbiome Products in Non-Pharmaceutical Industry
22.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
22.3. Applications of Microbiome Based Products in Agriculture Industry
22.4. Future Perspectives
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
24.1 Chapter Overview
24.2. Rebiotix
24.2.1. Company / Organization Snapshot
24.2.2. Interview Transcript: Lee Jones, President and Chief Executive Officer
24.3. S-Biomedic
24.3.1. Company / Organization Snapshot
24.3.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer
24.4. Pendulum Therpaeutics
24.4.1. Company / Organization Snapshot
24.4.2. Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer
24.5. Siolta Therapeutics
24.5.1. Company / Organization Snapshot
24.5.2. Interview Transcript: Nikole E Kimes, Founder and Vice President
24.6. Finch Therapeutics
24.6.1. Company / Organization Snapshot
24.6.2. Interview Transcript: James Burges, Co-Founder and Vice President of Innovation
24.7 Flame Biociences
24.7.1. Company / Organization Snapshot
24.7.2. Interview Transcript: JP Benya, Vice President, Business Development
24.8. List Biological Laboratories
24.8.1. Company / Organization Snapshot
24.8.2. Interview Transcript: Debbie Pinkston, Former Vice President, Sales and Business Development
24.9. Metabiomics
24.9.1. Company / Organization Snapshot
24.9.2. Interview Transcript: Gregory J Kuehn, President and Chief Operating Officer
24.10. Scioto Biosciences
24.10.1. Company / Organization Snapshot
24.10.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research
24.11. Stealth Startup
24.11.1. Company / Organization Snapshot
24.11.2. Interview Transcript: Alexander Segal, Founder
24.12. BiomX
24.12.1. Company / Organization Snapshot
24.12.2. Interview Transcript: Assaf Oron, Chief Business Officer
24.13. Da Volterra
24.13.1. Company / Organization Snapshot
24.13.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Strategy Officer
24.14. Chung Mei Pharmaceutical
24.14.1. Company / Organization Snapshot
24.14.2. Interview Transcript: Alexander Lin, Associate General Manager
24.15. Pacific Northwest National Laboratories
24.15.1. Company / Organization Snapshot
24.15.2. Interview Transcript: Aaron Wright, Senior Scientist
24.16. Quorum Innovations
24.16.1. Company / Organization Snapshot
24.16.2. Interview Transcript: Nicholas T. Monsul, Co-founder and Chairman
24.17. 4D Pharma
24.17.1. Company / Organization Snapshot
24.17.2. Interview Transcript: Charlie Badham, Senior Manager, Corporate Development
25. APPENDIX I: TABULATED DATA26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Benefits of the Human Microbiota
Figure 3.2 Factors Affecting Gut Microbiota
Figure 3.3 Factors Affecting Gut Microbiota in Infants
Figure 3.4 Impact of Diet on Gut Microbiota
Figure 3.5 Types of Microbiome-Based Therapeutics
Figure 3.6 Approaches to Design Microbiome Therapeutics
Figure 3.7 Health Benefits of Probiotics
Figure 3.8 Mechanism of Action of Probiotics
Figure 3.9 Beneficial Bacterial Strains for Probiotics
Figure 3.10 Key Achievements of the Human Microbiome Project (HMP)
Figure 3.11 Challenges Associated with the Development of Microbiome Therapeutics
Figure 4.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Figure 4.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Figure 4.3. Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Figure 4.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Figure 4.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
Figure 4.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
Figure 4.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 4.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Figure 4.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
Figure 4.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
Figure 4.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
Figure 4.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Figure 4.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Figure 4.15. Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Figure 4.11 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Figure 4.11 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
Figure 4.12 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 4.13 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Figure 4.14 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Figure 4.15 Microbiome Therapeutic Developers: Distribution by Company Size
Figure 4.16 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.17 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 4.18 Leading Drug Developers: Distribution by Number of Therapeutic Programs
Figure 5.1 Rebiotix: Financial Information, 2017-2021 (USD Million)
Figure 5.2 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
Figure 5.3 4D Pharma: Financial Information, 2017-2021 (USD Million)
Figure 6.1 Distribution by Trial Status
Figure 6.2 Distribution by Trial Registration Year
Figure 6.3 Distribution by Trial Registration Year and Type of Study
Figure 6.4 Distribution by Trial Phase and Trial Status
Figure 6.5 Year-wise Trend of Completed and Recruiting Trials
Figure 6.6 Distribution by Study Design
Figure 6.7 Distribution by Patient Enrollment
Figure 6.8 Distribution by Age Category
Figure 6.9 Distribution by Type of Sponsor / Collaborator
Figure 6.10 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.12 Distribution by Trial Location
Figure 6.13 Distribution by Trial Status and Geography
Figure 7.1 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Figure 7.2 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
Figure 7.3 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
Figure 7.4 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Figure 7.5 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Figure 7.6 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Figure 7.7 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Figure 7.8 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Figure 7.9 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
Figure 7.10 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
Figure 7.11 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
Figure 7.12 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
Figure 7.13 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
Figure 9.1 Working Mechanism of a Microflora Refinement System
Figure 9.2 Fecal Microbiota Transplantation: Distribution by Application Area
Figure 9.3 Fecal Microbiota Transplantation: Distribution by Status of Development
Figure 9.4 Fecal Microbiota Transplantation: Distribution by Target Indication
Figure 9.5 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
Figure 9.6 Fecal Microbiota Transplantation: Distribution by Route of Administration
Figure 9.7 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
Figure 9.8 Fecal Microbiota Transplantation Developers: Distribution by Company Size
Figure 9.9 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
Fgure 10.1 Fecal Microbiota Transplantation: Distribution by Trial Status
Figure 10.2 Fecal Microbiota Transplantation: Distribution by Trial Registration Year
Figure 10.3 Fecal Microbiota Transplantation: Distribution by Trial Registration Year and Type of Study
Figure 10.4 Fecal Microbiota Transplantation: Distribution by Trial Phase and Trial Status
Figure 10.5 Fecal Microbiota Transplantation: Year-wise Trend of Completed and Recruiting Trials
Figure 10.6 Fecal Microbiota Transplantation: Distribution by Study Design
Figure 10.7 Fecal Microbiota Transplantation: Distribution by Patient Enrollment
Figure 10.8 Fecal Microbiota Transplantation: Distribution by Age Category
Figure 10.9 Fecal Microbiota Transplantation: Distribution by Type of Sponsor / Collaborator
Figure 10.10 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 10.11 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 10.12 Fecal Microbiota Transplantation: Distribution by Trial Location
Figure 10.13 Fecal Microbiota Transplantation: Distribution by Trial Status and Geography
Figure 11.1 AC Matrix: Pictorial Representation
Figure 11.2 AC Matrix: Positioning of Different Indications
Figure 12.1 Heat Map Representation: Disttibution of Top Big Pharma Players
Figure 12.2 Big Pharma Players: Analysis by Portfolio Diversity
Figure 12.3 Big Pharma Players: Distribution by Phase of Development
Figure 12.4 Big Pharma Players: Distribution by Type of Molecule
Figure 12.5 Big Pharma Players: Distribution by Type of Therapy
Figure 12.6 Big Pharma Players: Distribution by Diversity of Therapeutic Areas
Figure 12.7 Spider Web Analysis: Company A
Figure 12.8 Spider Web Analysis: Company B
Figure 12.9 Spider Web Analysis: Company C
Figure 12.10 Spider Web Analysis: Company D
Figure 12.11 Spider Web Analysis: Company E
Figure 12.12 Spider Web Analysis: Company F
Figure 12.13 Spider Web Analysis: Company G
Figure 12.14 Spider Web Analysis: Company H
Figure 12.15 Spider Web Analysis: Company I
Figure 12.16 Spider Web Analysis: Company J
Figure 12.17 Spider Web Analysis: Company K
Figure 13.1 Benchmarking of Start-ups: Distribution by Portfolio Diversity
Figure 13.2 Benchmarking of Start-ups: Distribution by Phase of Development
Figure 13.3 Benchmarking of Start-ups: Distribution by Diversity in Therapeutic Areas
Figure 13.4 Benchmarking of Start-ups: Distribution by Funding Amount
Figure 13.5 Benchmarking of Start-ups: Distribution by Number of Investors
Figure 13.6 Benchmarking of Start-ups: Distribution by Type of Funding
Figure 13.7 Benchmarking of Start-ups: Distribution by Partnership Activity
Figure 13.8 Benchmarking of Start-ups: Distribution by Patent Portfolio
Figure 13.9 Start-up Health Indexing: Roots Analysis Perspective
Figure 14.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 14.2 Non-Insulin Therapies for Diabetes
Figure 14.3 Weight Categories as per BMI Calculations
Figure 14.4 Causes of Obesity in Children
Figure 14.5 Obese Population: Distribution by Key Regions
Figure 15.1 Funding and Investment Analysis: Cumulative Distribution by Year of Investment, 2017-2022
Figure 15.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2017-2022
Figure 15.4 Funding and Investment Analysis: Cumulative Distribution by Amount Invested, 2017-2022 (USD Million)
Figure 15.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2017-2022 (USD Million)
Figure 15.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
Figure 15.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2017-2022 (USD Million)
Figure 15.8 Funding and Investment Analysis: Summary of Amount Invested, 2017-2022 (USD Million)
Figure 15.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2017-2022 (USD Million)
Figure 15.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2017-2022 (USD Million)
Figure 15.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2017-2022 (USD Million)
Figure 15.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2017-2022 (USD Million)
Figure 15.13 Funding and Investment Analysis: Distribution by Target Indication
Figure 15.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2017-2022 (USD Million)
Figure 15.15 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 15.16 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2017-2022 (USD Million)
Figure 15.17 Funding and Investment Analysis: Distribution by Geography
Figure 15.18 Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 15.19 Most Active Players: Distribution by Number of Instances and Amount Invested, 2017-2022 (USD Million)
Figure 15.20 Most Active Investors: Distribution by Number of Instances
Figure 15.21 Funding and Investment Summary, 2017-2022 (USD Million)
Figure 16.1 Partnerships and Collaborations: Distribution of Year of Partnership
Figure 16.2 Partnerships and Collaborations: Distribution of Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution of Year and Type of Partnership
Figure 16.4 Partnerships and Collaborations: Distribution of Type of Product
Figure 16.5 Partnerships and Collaborations: Distribution of Target Indication
Figure 16.6 Partnerships and Collaborations: Distribution of Therapeutic Area
Figure 16.7 Partnerships and Collaborations: Distribution of Type of Company
Figure 16.8 Partnerships and Collaborations: Distribution of Type of Partner
Figure 16.9 Most Active Players: Distribution by Number of Partnerships
Figure 16.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 17.1 Microbiome Therapeutics Manufacturing Process
Figure 17.2 Challenges Associated with the Manufacturing of Microbiome Therapeutics
Figure 17.3 Strategies to Optimize Microbiome Therapeutic Manufacturing Operations
Figure 17.4 Microbiome Contract Manufacturers: Distribution by Year of Establishment
Figure 17.5 Microbiome Contract Manufacturers: Distribution by Company Size
Figure 17.6 Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Figure 17.7 Microbiome Contract Manufacturers: Distribution by Scale of Operation
Figure 17.8 Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 17.9 Microbiome Contract Manufacturers: Distribution by Type of Formulation
Figure 17.10 Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Figure 18.1 Big Data: The Three V’s
Figure 18.2 Internet of Things: Framework
Figure 18.3 Internet of Things: Applications in Healthcare
Figure 18.4 Big Data: Google Trends
Figure 18.4 Big Data and Microbiome: Google Trends
Figure 18.5 Big Data: Key Application Areas
Figure 18.6 Big Data: Opportunities in Healthcare
Figure 18.7 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
Figure 18.8 Challenges Associated with Microbiome-related Big Data Management
Figure 19.1 Microbiome Therapeutics Market: Forecast Methodology and Key Assumptions
Figure 19.2 Global Microbiome Therapeutics Market, 2022-2035 (USD Billion)
Figure 19.3 Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035
Figure 19.4 Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
Figure 19.5 Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
Figure 19.7 Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022 and 2035
Figure 19.8 Microbiome Therapeutics Market for Small Molecules, 2022-2035 (USD Million)
Figure 19.9 Microbiome Therapeutics Market for Biologics, 2022-2035 (USD Million)
Figure 19.10 Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
Figure 19.11 Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035 (USD Million)
Figure 19.12 Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
Figure 19.13 Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
Figure 19.14 Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
Figure 19.15 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035
Figure 19.16 Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Figure 19.17 Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 19.18 Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
Figure 119.19 Microbiome Therapeutics Market: Route of Administration, 2022-2035 (USD Million)
Figure 19.20 Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
Figure 19.21 Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
Figure 19.22 Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 19.23 Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
Figure 19.24 Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
Figure 19.25 Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 19.26 Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
Figure 19.27 Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035 (USD Million)
Figure 19.28 CP101 (Finch Therapeutics): Target Patient Population
Figure 19.29 CP101 (Finch Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 19.30 IBP-9414 (Infant Bacterial Therapeutics): Target Patient Population
Figure 19.31 IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 19.32 MaaT013 (MaaT Pharma): Target Patient Population
Figure 19.33 MaaT013 (MaaT Pharma): Sales Forecast, till 2035 (USD Million)
Figure 19.34 Oxabact® (OxThera): Target Patient Population
Figure 19.35 Oxabact® (OxThera): Sales Forecast, till 2035 (USD Million)
Figure 19.36 RBX2660 (Rebiotix): Target Patient Population
Figure 19.37 RBX2660 (Rebiotix): Sales Forecast, till 2035 (USD Million)
Figure 19.38 SER-109 (Seres Therapeutics): Target Patient Population
Figure 19.39 SER-109 (Seres Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 20.1 Microbiome Diagnostics Market: Forecast Methodology and Key Assumptions
Figure 20.2 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
Figure 20.3 Overall Microbiome Diagnostics Market, 2022-2035 (Units, Volume)
Figure 20.4 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
Figure 20.5 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (USD Million)
Figure 20.6 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
Figure 20.7 Microbiome Diagnostics Market for Diabetes, 2022-2035 (USD Million)
Figure 20.8 Microbiome Diagnostics Market for IBS, 2022-2035 (USD Million)
Figure 20.9 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (USD Million)
Figure 20.10 Microbiome Diagnostics Market for NASH, 2022-2035 (USD Million)
Figure 20.11 Microbiome Diagnostics Market for Obesity, 2022-2035 (USD Million)
Figure 20.12 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (USD Million)
Figure 20.13 Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (Units, Volume)
Figure 20.14 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (Units, Volume)
Figure 20.15 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (Units, Volume)
Figure 20.16 Microbiome Diagnostics Market for Diabetes, 2022-2035 (Units, Volume)
Figure 20.17 Microbiome Diagnostics Market for IBS, 2022-2035 (Units, Volume)
Figure 20.18 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (Units, Volume)
Figure 20.19 Microbiome Diagnostics Market for NASH, 2022-2035 (Units, Volume)
Figure 20.20 Microbiome Diagnostics Market for Obesity, 2022-2035 (Units, Volume)
Figure 20.21 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (Units, Volume)
Figure 20.22 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
Figure 20.23 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Figure 20.24 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
Figure 20.25 Microbiome Diagnostics Market for Oncology, 2022-2035 (USD Million)
Figure 20.26 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (Units, Volume)
Figure 20.27 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (Units, Volume)
Figure 20.28 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (Units, Volume)
Figure 20.29 Microbiome Diagnostics Market for Oncology, 2022-2035 (Units, Volume)
Figure 20.30 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (USD Million)
Figure 20.31 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (USD Million)
Figure 20.32 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (USD Million)
Figure 20.33 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (USD Million)
Figure 20.34 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (Units, Volume)
Figure 20.35 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (Units, Volume)
Figure 20.36 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (Units, Volume)
Figure 20.37 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (Units, Volume)
Figure 20.38 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.39 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
Figure 20.40 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
Figure 20.41 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 20.42 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (Units, Volume)
Figure 20.43 Microbiome Diagnostics Market in North America, 2022-2035 (Units, Volume)
Figure 20.44 Microbiome Diagnostics Market in Europe, 2022-2035 (Units, Volume)
Figure 20.45 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (Units, Volume)
Figure 21.1 Fecal Microbiota Therapies: Forecast Methodology and Key Assumptions
Figure 21.2 Overall FMT Market, 2022-2035 (USD Million)
Figure 21.3 Overall FMT Market, 2022-2035 (Units, Volume)
Figure 21.4 Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
List Of Tables
Table 3.1 Types of Microbiota in the Gastrointestinal Tract
Table 3.2 Common Instances of Misuse of Antibiotics
Table 3.3 Impact of Antibiotics on Intestinal Microflora
Table 3.4 List of Microorganisms Classified as Class I Carcinogens by the IARC
Table 3.5 Relationship Between Microbiome and Disease Progression
Table 3.6 Impact of Drug-Microbiome Interactions
Table 3.7 List of Foods Containing Prebiotics
Table 4.1 Microbiome Therapeutics: Clinical Pipeline
Table 4.2 Clinical Phase Microbiome Therapeutics: Information on Type of Molecule and Route of Administration
Table 4.3 Clinical Phase Microbiome Therapeutics: Additional Information
Table 4.4 Microbiome Therapeutics: Preclinical Pipeline
Table 4.5 Preclinical Phase Microbiome Therapeutics: Additional Information
Table 4.6 Microbiome Therapeutics: List of Drug Developers
Table 5.1 Microbiome Therapeutic Developers: Companies with Candidates in Highest Phase of Development
Table 5.2 Finch Therapeutics: Microbiome-Based Product Portfolio
Table 5.3 CP101: Current Status of Development
Table 5.4 CP101: Clinical Studies
Table 5.5 Finch Therapeutics: Recent Developments and Future Outlook
Table 5.6 Infant Bacterial Therapeutics: Microbiome-Based Product Portfolio
Table 5.7 IBP-9414: Current Status of Development
Table 5.8 IBP-9414: Clinical Studies
Table 5.9 Infant Bacterial Therapeutics: Recent Developments and Future Outlook
Table 5.10 MaaT Pharma: Microbiome-Based Product Portfolio
Table 5.11 MaaT013: Current Status of Development
Table 5.12 MaaT013: Clinical Studies
Table 5.13 MaaT Pharma: Recent Developments and Future Outlook
Table 5.14 OxThera: Microbiome-Based Product Portfolio
Table 5.15 Oxabact: Current Status of Development
Table 5.16 Oxabact: Clinical Studies
Table 5.17 OxThera: Recent Developments and Future Outlook
Table 5.18 Rebiotix: Microbiome-Based Product Portfolio
Table 5.19 RBX2660: Current Status of Development
Table 5.20 RBX2660: Clinical Studies
Table 5.21 Rebiotix: Recent Developments and Future Outlook
Table 5.22 Seres Therapeutics: Microbiome-Based Product Portfolio
Table 5.23 SER-109: Current Status of Development
Table 5.24 SER-109: Clinical Studies
Table 5.25 Seres Therapeutics: Recent Developments and Future Outlook
Table 5.26 Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
Table 5.27 4D Pharma: Financial Information
Table 5.28 4D Pharma: Recent Developments and Future Outlook
Table 5.29 Biosortia Pharmaceuticals: Recent Developments and Future Outlook
Table 5.30 Qu Biologics: Recent Developments and Future Outlook
Table 5.31 Servatus: Recent Developments and Future Outlook
Table 6.1 Microbiome Therapeutics: List of Clinical Trials
Table 7.1 Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Development Pipeline
Table 7.2 Microbiome Diagnostics and Screening / Profiling Tests: List of Developers
Table 8.1 Shoreline Biome: Company Overview
Table 8.2 Shoreline Biome: Microbiome Test Portfolio
Table 8.3 Shoreline Biome: Recent Developments and Future Outlook
Table 8.4 DNA Genotek: Company Overview
Table 8.5 DNA Genotek: Microbiome Test Portfolio
Table 8.6 DNA Genotek: Recent Developments and Future Outlook
Table 8.7 Invivo Healthcare: Company Overview
Table 8.8 Invivo Healthcare: Microbiome Test Portfolio
Table 8.9 Invivo Healthcare: Recent Developments and Future Outlook
Table 8.10 GoodGut: Company Overview
Table 8.11 GoodGut: Microbiome Test Portfolio
Table 8.12 GoodGut: Recent Developments and Future Outlook
Table 8.13 BiomeDx: Company Overview
Table 8.14 BiomeDx: Microbiome Test Portfolio
Table 8.15 BiomeDx: Recent Developments and Future Outlook
Table 9.1 Comparison between Various Routes of Administration of FMT
Table 9.2 FMT: Summary of Clinical Guidelines
Table 9.3 FMT: Summary of Insurance Coverage Payer
Table 9.4 FMT: Marketed and Development Pipeline
Table 9.5 FMT: List of Developers
Table 9.6 List of Stool Banks for FMT Development
Table 9.7 Fecal Microbiota Transplant and Human Microbiome Transplant (HMT): Key Differences in Processing
Table 9.8 Flora Medicine: Fecal Microbiota Transplant Treatment Cost
Table 9.9 OpenBiome: Types of FMT Formulations
Table 10.1 Fecal Microbiota Transplant: List of Registered Clinical Trials
Table 14.1 Diabetes: Current Treatment Options
Table 14.2 Diabetes: Side Effects of Current Treatment Options
Table 14.3 Microbiome Therapeutics Candidates for Diabetes
Table 14.4 Microbiome Therapeutics Candidates for Lactose Intolerance
Table 14.5 Microbiome Therapeutics Candidates for NASH
Table 14.6 Microbiome Therapeutics Candidates for Primary Hyperoxaluria
Table 14.7 Obesity: Side Effects of Current Treatment Options
Table 14.8 Microbiome Therapeutic Candidates for Obesity
Table 14.9 Crohn’s Disease: Current Treatment Options
Table 14.10 Crohn’s Disease: Side Effects of Current Treatment Options
Table 14.11 Microbiome Therapeutics Candidates for Crohn’s Disease
Table 14.12 IBS: Current Treatment Options
Table 14.13 Microbiome Therapeutics Candidates for IBS
Table 14.14 Ulcerative Colitis: Current Treatment Options
Table 14.15 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 14.16 Microbiome Therapeutics Candidates for Ulcerative Colitis
Table 14.17 Colorectal Cancer: Side Effects of Current Treatment Options
Table 14.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
Table 14.19 Lung Cancer: Current Treatment Options
Table 14.20 Lung Cancer: Side Effects of Current Treatment Options
Table 14.21 Microbiome Therapeutics Candidates for Lung Cancer
Table 14.22 Acne Vulgaris: Current Treatment Options
Table 14.23 Acne Vulgaris: Side Effects of Current Treatment Options
Table 14.24 Microbiome Therapeutics Candidates for Acne Vulgaris
Table 14.25 CDI: Diagnostic Testing
Table 14.26 CDI: Severity Scoring System and Treatment Options
Table 14.27 CDI: Side Effects of Current Treatment Options
Table 14.28 Microbiome Therapeutics Candidates for CDI
Table 14.29 Bacterial Vaginosis: Current Treatment Options
Table 14.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
Table 14.31 Microbiome Therapeutics Candidates for Bacterial Vaginosis
Table 15.1 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, 2017-2022 (till March)
Table 15.2 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, 2017-2022 (till March)
Table 15.3 Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Location of Headquarters, 2017-2022 (till March)
Table 16.1 Human Microbiome: List of Partnerships and Collaborations, 2017-2022 (till March)
Table 17.1 Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size, Accreditation Received and Scale of Operation
Table 17.2 Microbiome Contract Manufacturers: Information on Type of Product Manufactured
Table 17.2 Microbiome Contract Manufacturers: Information on Type of Formulation
Table 17.6 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
Table 18.1 List of Companies Using Big Data for Microbiome Research
Table 18.2 Human Longevity: Partnerships and Collaborations
Table 18.3 Human Longevity: Venture Capital Funding
Table 18.4 Resilient Biotics: Venture Capital Funding
Table 19.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
Table 19.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
Table 23.1 S-Biomedic: Company Snapshot
Table 23.2 Pendulum Therapeutics: Company Snapshot
Table 23.3 Siolta Therapeutics: Company Snapshot
Table 23.4 OpenBiome: Company Snapshot
Table 23.5 Assembly Biosciences: Company Snapshot
Table 23.6 List Biological Laboratories: Company Snapshot
Table 23.7 Metabiomics: Company Snapshot
Table 23.8 Microbiome Therapeutics: Company Snapshot
Table 23.9 Universal Stabilization Technologies: Company Snapshot
Table 23.10 BiomX: Company Snapshot
Table 23.11 Da Volterra: Company Snapshot
Table 23.12 Chung Mei Pharmaceutical: Company Snapshot
Table 23.13 Pacific Northwest National Laboratories: Company Snapshot
Table 23.14 Quorum Innovations: Company Snapshot
Table 23.15 4D Pharma: Company Snapshot
Table 24.1 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Table 24.2 Clinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Table 24.3 Clinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 24.4 Clinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Table 24.5 Clinical Phase Microbiome Therapeutics: Distribution by Type of Product
Table 24.6 Clinical Phase Microbiome Therapeutics: Distribution by Target Indication
Table 24.7 Clinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Table 24.8 Clinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Table 24.9 Clinical Phase Microbiome Therapeutics: Distribution by Type of Formulation
Table 24.10 Clinical Phase Microbiome Therapeutics: Distribution by Dose Frequency
Table 24.11 Clinical Phase Microbiome Therapeutics: Distribution by Type of Therapy
Table 24.12 Clinical Phase Microbiome Therapeutics: Distribution by Combination Drug
Table 24.13 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development
Table 24.14 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Molecule
Table 24.15 Preclinical Phase Microbiome Therapeutics: Distribution by Phase of Development and Type of Molecule
Table 24.16 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Biologic
Table 24.17 Preclinical Phase Microbiome Therapeutics: Distribution by Type of Product
Table 24.18 Preclinical Phase Microbiome Therapeutics: Distribution by Target Indication
Table 24.19 Preclinical Phase Microbiome Therapeutics: Distribution by Therapeutic Area
Table 24.20 Preclinical Phase Microbiome Therapeutics: Distribution by Route of Administration
Table 24.21 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Table 24.22 Microbiome Therapeutic Developers: Distribution by Company Size
Table 24.23 Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Table 24.24 Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Table 24.25 Leading Drug Developers: Distribution by Number of Therapeutic Programs
Table 24.26 Rebiotix: Financial Information, 2017-2021 (USD Million)
Table 24.27 Seres Therapeutics: Financial Information, 2017-2021 (USD Million)
Table 24.28 4D Pharma: Financial Information, 2017-2021 (USD Million)
Table 24.29 Distribution by Trial Status
Table 24.30 Distribution by Trial Registration Year
Table 24.31 Distribution by Trial Registration Year and Type of Study
Table 24.32 Distribution by Trial Phase and Trial Status
Table 24.33 Year-wise Trend of Completed and Recruiting Trials
Table 24.34 Distribution by Study Design
Table 24.35 Distribution by Patient Enrollment
Table 24.36 Distribution by Age Category
Table 24.37 Distribution by Type of Sponsor / Collaborator
Table 24.38 Most Active Industry Players: Distribution by Number of Registered Trials
Table 24.39 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 24.40 Distribution by Trial Location
Table 24.41 Distribution by Trial Status and Geography
Table 24.42 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Table 24.43 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Test
Table 24.44 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development and Type of Test
Table 24.45 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Table 24.46 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Table 24.47 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Table 24.48 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Table 24.49 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Table 24.50 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Year of Establishment
Table 24.51 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size
Table 24.52 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Location of Headquarters
Table 24.53 Microbiome Diagnostic and Screening / Profiling Tests Providers: Distribution by Company Size and Location of Headquarters
Table 24.54 Most Active Microbiome Test Providers: Distribution by Number of Microbiome Tests
Table 24.55 Working Mechanism of a Microflora Refinement System
Table 24.56 Fecal Microbiota Transplantation: Distribution by Application Area
Table 24.57 Fecal Microbiota Transplantation: Distribution by Status of Development
Table 24.58 Fecal Microbiota Transplantation: Distribution by Target Indication
Table 24.59 Fecal Microbiota Transplantation: Distribution by Therapeutic Area
Table 24.60 Fecal Microbiota Transplantation: Distribution by Route of Administration
Table 24.61 Fecal Microbiota Transplantation Developers: Distribution by Year of Establishment
Table 24.62 Fecal Microbiota Transplantation Developers: Distribution by Company Size
Table 24.63 Fecal Microbiota Transplantation Developers: Distribution by Location of Headquarters
Table 24.64 Fecal Microbiota Transplantation: Distribution by Trial Status
Table 24.65 Fecal Microbiota Transplantation: Distribution by Trial Registration Year
Table 24.66 Fecal Microbiota Transplantation: Distribution by Trial Registration Year and Type of Study
Table 24.67 Fecal Microbiota Transplantation: Distribution by Trial Phase and Trial Status
Table 24.68 Fecal Microbiota Transplantation: Year-wise Trend of Completed and Recruiting Trials
Table 24.69 Fecal Microbiota Transplantation: Distribution by Study Design
Table 24.70 Fecal Microbiota Transplantation: Distribution by Patient Enrollment
Table 24.71 Fecal Microbiota Transplantation: Distribution by Age Category
Table 24.72 Fecal Microbiota Transplantation: Distribution by Type of Sponsor / Collaborator
Table 24.73 Most Active Industry Players: Distribution by Number of Registered Trials
Table 24.74 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 24.75 Fecal Microbiota Transplantation: Distribution by Trial Location
Table 24.76 Fecal Microbiota Transplantation: Distribution by Trial Status and Geography
Table 24.77 Big Pharma Players: Analysis by Portfolio Diversity
Table 24.78 Big Pharma Players: Distribution by Phase of Development
Table 24.79 Big Pharma Players: Distribution by Type of Molecule
Table 24.80 Big Pharma Players: Distribution by Type of Therapy
Table 24.81 Big Pharma Players: Distribution by Diversity of Therapeutic Areas
Table 24.82 Benchmarking of Start-ups: Distribution by Portfolio Diversity
Table 24.83 Benchmarking of Start-ups: Distribution by Phase of Development
Table 24.84 Benchmarking of Start-ups: Distribution by Diversity in Therapeutic Areas
Table 24.85 Benchmarking of Start-ups: Distribution by Funding Amount
Table 24.86 Benchmarking of Start-ups: Distribution by Number of Investors
Table 24.87 Benchmarking of Start-ups: Distribution by Type of Funding
Table 24.88 Benchmarking of Start-ups: Distribution by Partnership Activity
Table 24.89 Benchmarking of Start-ups: Distribution by Patent Portfolio
Table 24.90 Start-up Health Indexing: Roots Analysis Perspective
Table 24.91 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Table 24.92 Non-Insulin Therapies for Diabetes
Table 24.93 Weight Categories as per BMI Calculations
Table 24.94 Causes of Obesity in Children
Table 24.95 Obese Population: Distribution by Key Regions
Table 24.96 Funding and Investment Analysis: Cumulative Distribution by Year of Investment, 2017-2022
Table 24.97 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2017-2022
Table 24.98 Funding and Investment Analysis: Cumulative Distribution by Amount Invested, 2017-2022 (USD Million)
Table 24.99 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2017-2022 (USD Million)
Table 24.100 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2017-2022
Table 24.101 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2017-2022 (USD Million)
Table 24.102 Funding and Investment Analysis: Summary of Amount Invested, 2017-2022 (USD Million)
Table 24.103 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2017-2022 (USD Million)
Table 24.104 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2017-2022 (USD Million)
Table 24.105 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2017-2022 (USD Million)
Table 24.106 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2017-2022 (USD Million)
Table 24.107 Funding and Investment Analysis: Distribution by Target Indication
Table 24.108 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2017-2022 (USD Million)
Table 24.109 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 24.110 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2017-2022 (USD Million)
Table 24.111 Funding and Investment Analysis: Distribution by Geography
Table 24.112 Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 24.113 Most Active Players: Distribution by Number of Instances and Amount Invested, 2017-2022 (USD Million)
Table 24.114 Most Active Investors: Distribution by Number of Instances
Table 24.115 Funding and Investment Summary, 2017-2022 (USD Million)
Table 24.116 Partnerships and Collaborations: Distribution of Year of Partnership
Table 24.117 Partnerships and Collaborations: Distribution of Type of Partnership
Table 24.118 Partnerships and Collaborations: Distribution of Year and Type of Partnership
Table 24.119 Partnerships and Collaborations: Distribution of Type of Product
Table 24.120 Partnerships and Collaborations: Distribution of Target Indication
Table 24.121 Partnerships and Collaborations: Distribution of Therapeutic Area
Table 24.122 Partnerships and Collaborations: Distribution of Type of Company
Table 24.123 Partnerships and Collaborations: Distribution of Type of Partner
Table 24.124 Most Active Players: Distribution by Number of Partnerships
Table 24.125 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 24.126 Microbiome Contract Manufacturers: Distribution by Year of Establishment
Table 24.127 Microbiome Contract Manufacturers: Distribution by Company Size
Table 24.128 Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Table 24.129 Microbiome Contract Manufacturers: Distribution by Scale of Operation
Table 24.130 Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Table 24.131 Microbiome Contract Manufacturers: Distribution by Type of Formulation
Table 24.132 Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Table 24.133 Microbiome Therapeutics Market: Forecast Methodology and Key Assumptions
Table 24.134 Global Microbiome Therapeutics Market, 2022-2035 (USD Billion)
Table 24.135 Microbiome Therapeutics Market: Distribution by Type of Product, 2022 and 2035
Table 24.136 Microbiome Therapeutics Market for Probiotic Drugs, 2022-2035 (USD Million)
Table 24.137 Microbiome Therapeutics Market for Other Drugs, 2022-2035 (USD Million)
Table 24.138 Microbiome Therapeutics Market: Distribution by Type of Molecule, 2022 and 2035
Table 24.139 Microbiome Therapeutics Market for Small Molecules, 2022-2035 (USD Million)
Table 24.140 Microbiome Therapeutics Market for Biologics, 2022-2035 (USD Million)
Table 24.141 Microbiome Therapeutics Market: Distribution by Target Disease Indication, 2022 and 2035
Table 24.142 Microbiome Therapeutics Market for Graft Versus Host Disease, 2022-2035 (USD Million)
Table 24.143 Microbiome Therapeutics Market for Necrotizing Enterocolitis, 2022-2035 (USD Million)
Table 24.144 Microbiome Therapeutics Market for Primary Hyperoxaluria, 2022-2035 (USD Million)
Table 24.145 Microbiome Therapeutics Market for Recurrent C. difficile Infection, 2022-2035 (USD Million)
Table 24.146 Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2022 and 2035
Table 24.147 Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Table 24.148 Microbiome Therapeutics Market for Infectious Diseases, 2022-2035 (USD Million)
Table 24.149 Microbiome Therapeutics Market for Rare Disorders, 2022-2035 (USD Million)
Table 24.150 Microbiome Therapeutics Market: Route of Administration, 2022-2035 (USD Million)
Table 24.151 Microbiome Therapeutics Market for Oral Therapeutics, 2022-2035 (USD Million)
Table 24.152 Microbiome Therapeutics Market for Rectal Therapeutics, 2022-2035 (USD Million)
Table 24.153 Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 24.154 Microbiome Therapeutics Market in North America, 2022-2035 (USD Million)
Table 24.155 Microbiome Therapeutics Market in Europe, 2022-2035 (USD Million)
Table 24.156 Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 24.157 Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2022-2035 (USD Million)
Table 24.158 Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035 (USD Million)
Table 24.159 CP101 (Finch Therapeutics): Sales Forecast, till 2035 (USD Million)
Table 24.160 IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2035 (USD Million)
Table 24.161 MaaT013 (MaaT Pharma): Sales Forecast, till 2035 (USD Million)
Table 24.162 Oxabact® (OxThera): Sales Forecast, till 2035 (USD Million)
Table 24.163 RBX2660 (Rebiotix): Sales Forecast, till 2035 (USD Million)
Table 24.164 SER-109 (Seres Therapeutics): Sales Forecast, till 2035 (USD Million)
Table 24.165 Microbiome Diagnostics Market: Forecast Methodology and Key Assumptions
Table 24.166 Overall Microbiome Diagnostics Market, 2022-2035 (USD Million)
Table 24.167 Overall Microbiome Diagnostics Market, 2022-2035 (Units, Volume)
Table 24.168 Microbiome Diagnostics Market: Distribution by Target Indications, 2022-2035 (USD Million)
Table 24.169 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (USD Million)
Table 24.170 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (USD Million)
Table 24.171 Microbiome Diagnostics Market for Diabetes, 2022-2035 (USD Million)
Table 24.172 Microbiome Diagnostics Market for IBS, 2022-2035 (USD Million)
Table 24.173 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (USD Million)
Table 24.174 Microbiome Diagnostics Market for NASH, 2022-2035 (USD Million)
Table 24.175 Microbiome Diagnostics Market for Obesity, 2022-2035 (USD Million)
Table 24.176 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (USD Million)
Table 24.177 Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035 (Units, Volume)
Table 24.178 Microbiome Diagnostics Market for Crohn’s Disease, 2022-2035 (Units, Volume)
Table 24.179 Microbiome Diagnostics Market for Colorectal Cancer, 2022-2035 (Units, Volume)
Table 24.180 Microbiome Diagnostics Market for Diabetes, 2022-2035 (Units, Volume)
Table 24.181 Microbiome Diagnostics Market for IBS, 2022-2035 (Units, Volume)
Table 24.182 Microbiome Diagnostics Market for Lung Cancer, 2022-2035 (Units, Volume)
Table 24.183 Microbiome Diagnostics Market for NASH, 2022-2035 (Units, Volume)
Table 24.184 Microbiome Diagnostics Market for Obesity, 2022-2035 (Units, Volume)
Table 24.185 Microbiome Diagnostics Market for Ulcerative Colitis, 2022-2035 (Units, Volume)
Table 24.186 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (USD Million)
Table 24.187 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (USD Million)
Table 24.188 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (USD Million)
Table 24.189 Microbiome Diagnostics Market for Oncology, 2022-2035 (USD Million)
Table 24.190 Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2022-2035 (Units, Volume)
Table 24.191 Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2022-2035 (Units, Volume)
Table 24.192 Microbiome Diagnostics Market for Metabolic Disorders, 2022-2035 (Units, Volume)
Table 24.193 Microbiome Diagnostics Market for Oncology, 2022-2035 (Units, Volume)
Table 24.194 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (USD Million)
Table 24.195 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (USD Million)
Table 24.196 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (USD Million)
Table 24.197 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (USD Million)
Table 24.198 Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035 (Units, Volume)
Table 24.199 Microbiome Diagnostics Market for Hospital Pharmacies, 2022-2035 (Units, Volume)
Table 24.200 Microbiome Diagnostics Market for Retail Pharmacies, 2022-2035 (Units, Volume)
Table 24.201 Microbiome Diagnostics Market for Online Pharmacies, 2022-2035 (Units, Volume)
Table 24.202 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 24.203 Microbiome Diagnostics Market in North America, 2022-2035 (USD Million)
Table 24.204 Microbiome Diagnostics Market in Europe, 2022-2035 (USD Million)
Table 24.205 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 24.206 Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035 (Units, Volume)
Table 24.207 Microbiome Diagnostics Market in North America, 2022-2035 (Units, Volume)
Table 24.208 Microbiome Diagnostics Market in Europe, 2022-2035 (Units, Volume)
Table 24.209 Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2022-2035 (Units, Volume)
Table 24.210 Fecal Microbiota Therapies: Forecast Methodology and Key Assumptions
Table 24.211 Overall FMT Market, 2022-2035 (USD Million)
Table 24.212 Overall FMT Market, 2022-2035 (Units, Volume)
Table 24.213 Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

Companies Mentioned

  • 4D Pharma
  • 8VC
  • Aarhus University
  • Abdul Latif Jameel Health
  • Abstract Ventures
  • Acequia Capital
  • Adapsyn Bioscience
  • Adare Pharmaceuticals (acquired by THL and Frazier)
  • ADM Biopolis
  • AgroParisTech
  • Alexandria Venture Investments
  • Alveolus Bio (subsidiary of ResBiotic)
  • American Gastroenterological Association (AGA)
  • Anatara Life Sciences
  • AOBiome Therapeutics
  • Applied Biosystems
  • Ardigen
  • Arena Pharmaceuticals
  • Armata Pharmaceuticals
  • Arranta Bio
  • ARTIS Ventures
  • ARTPred
  • Asia Microbiota Bank
  • AstraZeneca
  • Atlas Biomed
  • Atmo Biosciences
  • Auggi (acquired by Seed Health)
  • Aumgene Biosciences
  • Auriga Partners
  • Austrian Research Promotion Agency (FFG)
  • Autism Impact Fund
  • Axial Biotherapeutics
  • Azenta Life Sciences
  • Azitra
  • Bacthera
  • Bayer
  • BBG Ventures
  • BD (Becton, Dickinson and Company)
  • Beiersdorf
  • Ben Franklin Technology Partners
  • Bill & Melinda Gates Foundation
  • BIOASTER
  • BioCat
  • Biocodex
  • BioCrossroads
  • BioGaia
  • Biohit
  • Biomathematica 
  • Bio-Me
  • BiomeBank
  • Biomecite Diagnostics
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BioMeD X
  • Biomica
  • Biomics
  • BiomX
  • Bios Partners
  • Biose
  • Biosortia Pharmaceuticals
  • BJP Laboratories
  • Blue Turtle Bio
  • Boehringer Ingelheim
  • Boston Children's Hospital
  • BoxGroup
  • Bpifrance
  • Bristol Myers Squibb
  • British Patient Capital
  • C.R. Bard (acquired by BD (Becton, Dickinson and Company))
  • C3J Therapeutics
  • Caelus Health
  • Cambridge Innovation Capital
  • Cambridge University Hospitals NHS Foundation Trust
  • Cancer Research UK
  • Candela Paramount
  • Cap Innov’Est
  • Capsugel (acquired by Lonza)
  • Carbiotix
  • cerascreen
  • Cerbios-Pharma
  • CHAIN Biotech
  • Chromaderm (acquired by DermBiont)
  • ChunLab
  • City of Hope
  • Civet BioSciences
  • Civilization Ventures
  • CJ Group
  • ClostraBio
  • Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
  • Congruent Ventures 
  • Connecticut Innovations
  • COPD Foundation
  • CoreBiome
  • Cornell University
  • Corundum Systems Biology
  • CosmosID
  • Crédit Mutuel Innovation
  • Crestovo
  • Crown Laboratories
  • Cykinso
  • Cytognos
  • Da Volterra
  • Dana-Farber Cancer Institute
  • Danone Manifesto Ventures
  • Darling Ventures
  • Debiopharm
  • DeepBiome Therapeutics
  • Department of Defense (DoD)
  • DermBiont
  • Diagnostic Solutions
  • Diversigen
  • DNA Genotek
  • DoctorsForMe (acquired by Human Longevity)
  • Domain Associates
  • DSM Venturing
  • Eagle Biosciences 
  • Edico Genome (acquired by Illumina)
  • EirGenix
  • Elevate Ventures
  • Emerging Technologies Partners
  • Endoscopy Center of Red Bank
  • Enterin
  • Enterome
  • Equipo Ventures
  • Eurofins ADME BIOANALYSES
  • European Innovation Council (EIC)
  • European Union
  • Evelo Biosciences
  • Evologic Technologies
  • Evvy
  • Exeliom Biosciences
  • Ferring Pharmaceuticals
  • Filgen
  • Finch Therapeutics
  • Flora Medicine
  • Floragraph
  • Fonterra
  • Founders Fund
  • FUJIFILM Diosynth Biotechnologies
  • G9 Ventures
  • Galmed Pharmaceuticals
  • Genentech
  • General Catalyst
  • Genetic Analysis
  • Genetimes Technology
  • GENEWIZ
  • Genome & Company
  • Genopole
  • Genorama
  • Genosys
  • Genova Diagnostics
  • Gilead Sciences
  • Ginkgo Bioworks
  • GISEV
  • Global Brain
  • Goodgut
  • Groken Bioscience
  • GlaxoSmithKline
  • Gustave Roussy
  • Gusto Global
  • Hadasit Medical Research Services and Development 
  • Harvard T.H. Chan School of Public Health
  • Harvard University
  • Heidelberg University
  • Hemi Ventures
  • Hercules Capital
  • Heritage Medical Systems
  • HIPRA
  • Holobiome
  • Hudson Institute of Medical Research
  • Human Longevity
  • Human Ventures
  • iCarbonX
  • Igen Biolab Group
  • Illumina
  • ImmuneBiotech
  • Immuron
  • inBiome
  • Indie Asset Partners
  • Infant Bacterial Therapeutics
  • Innovate UK
  • Inpac Probiotics 
  • INRAE
  • Integrated BioBank of Luxembourg (IBBL)
  • Integrated Sciences
  • Invivo Healthcare
  • IP Group
  • Ixcela
  • Janssen
  • Jeneil Biotech
  • John Theurer Cancer Center
  • Johnson & Johnson
  • Joyance Partners
  • JSR 
  • Juno Bio
  • K3 Ventures
  • Kairos Ventures
  • Kaleido Biosciences
  • Karolinska Institutet
  • KdT Ventures
  • Keiretsu Capital 
  • Khosla Ventures
  • Leadiant Biosciences
  • Leiden University Medical Center
  • Leucine Rich Bio
  • Life Genomics
  • Life Sciences Fund Amsterdam (LSFA)
  • Life Sciences Partners
  • List Biological Laboratories
  • LIVEYOUNGER Institute
  • Locus Biosciences
  • Longevity Acquisition Corporation (a subsidiary of 4D Pharma)
  • Longwood Fund
  • LUCA Biologics
  • Luina Bio
  • Lundbeckfonden Foundation
  • Lunsford Capital
  • Luxia Scientific
  • MaaT Pharma
  • Macrogen
  • Maruho
  • Massachusetts General Hospital
  • MassChallenge Switzerland
  • MatriSys Bioscience
  • Mayo Clinic
  • MD Anderson Cancer Center
  • MegpPharm 
  • Memorial Sloan Kettering Cancer Center 
  • Merck
  • Metabiomics (a subsidiary of Prescient Medicine)
  • MetaboGen
  • MetaGenoPolis
  • Meteoric Biopharmaceuticals
  • Microba
  • Microbio
  • Microbiome Diagnostic Partners
  • Microbiome Research Centre
  • Microbiotica
  • Micronoma
  • Microviable Therapeutics
  • Mii Fund
  • Mirna Therapeutics
  • Mitchell Cancer Institute, University of South Alabama
  • MyBiotics
  • MyDiagnostics
  • MyMicroZoo
  • Naked Biome
  • Nascita Ventures
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institutes of Health (NIH) 
  • National Instituteof Allergy and Infectious Diseases (NIAID) 
  • National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
  • National Science Foundation (NSF)
  • Naval Medical Research Center
  • Nestlé Health Science
  • New Ventures
  • Next Act Fund
  • NextBiotics
  • NIZO
  • Notitia Biotechnologies
  • Novo Nordisk
  • Novozymes
  • NuBiyota
  • NYU Langone Health
  • OCA Ventures
  • Olive Tree Capital
  • Ombre
  • One Codex 
  • OneVentures
  • OpenBiome
  • OptiBiotix Health
  • Oracle
  • Orion Fund
  • Osaka University Venture
  • OSbiome
  • Osel
  • Oxford Vacmedix
  • OxThera
  • Pacira Pharmaceuticals (formerly known as SkyePharma)
  • Palex Medical
  • Pangaea Ventures
  • Paris-Saclay University
  • Parkinson's UK
  • Pfizer
  • Phase Genomics
  • Phi Therapeutics
  • PHYZEN
  • Pivotal Life Sciences
  • PivotNorth Capital
  • Plug & Play Ventures
  • Polsky Center
  • Precigen ActoBio™
  • SOLVD Health (formerly known as Prescient Medicine Holdings)
  • Primer Capital
  • ProbioFerm
  • Probiotical
  • Probiotics Australia
  • ProdermIQ
  • Protexin
  • Psomagen
  • Qingdao Institute of Bioenergy and Bioprocess Technology 
  • Qu Biologics
  • Quay Pharma
  • Queen Elizabeth Hospital
  • Quorum Innovations
  • Rambam Health Care Campus
  • Rebiotix
  • Relevance Ventures
  • Resilient Biotics
  • Resphera Biosciences
  • Rev1 Ventures
  • Rise Therapeutics
  • Roche
  • Rocky Mountain Analytical (RMA)
  • RondinX (acquired by BiomX)
  • Roswell Park Comprehensive Cancer Center
  • Sacco
  • S-Biomedic
  • Scanwell Health 
  • SciBac
  • Sciencewerke
  • Scioto Biosciences
  • Second Genome
  • Seed Health
  • Seres Therapeutics
  • Servatus
  • Seventure Partners
  • SeylanMED (acquired by DermBiont)
  • SFA Therapeutics
  • Shanda Group
  • Shoreline Biome
  • Siolta Therapeutics
  • Skive Hospital
  • SNIPR Biome
  • Social Starts
  • Sofimac Innovation
  • SOSV
  • Spanish National Research Council (CSIC)
  • Standard Process
  • Stanford Cancer Institute
  • Stanford Health Care
  • Stanford University School of Medicine
  • Statens Serum Institut
  • Stellate Therapeutics
  • Stora Sköndal
  • Sun Genomics
  • Swiss Integrative Center for Human Health (SICHH)
  • Symberix
  • Symbiosis Pharma
  • Symbiotic Health
  • Symbiotix Biotherapies
  • Synlogic
  • Synthetic Biologics
  • Taiho Ventures
  • Takeda
  • Tech Coast Angels
  • Tencent Holdings
  • Thalys Medical Technology Group 
  • The BioCollective
  • The Craftory
  • The Michael J. Fox Foundation for Parkinson's Research
  • The North Carolina Biotechnology Center
  • The Seerave Foundation
  • TNO
  • Toba Capital
  • Trail Mix Ventures (TMV)
  • Trayer Biotherapeutics
  • UAS Labs
  • uBiome
  • Unilever Ventures
  • Unique Biotech
  • University of Adelaide
  • University of Birmingham
  • University of California San Diego School of Medicine
  • University of Chicago
  • University of Minnesota
  • University of New South Wales
  • University of North Carolina
  • University of Nottingham
  • University of Queensland
  • University of Verona
  • Unpopular Ventures
  • UTokyo Innovation Platform
  • Vaiomer
  • Varinos
  • Vedanta Biosciences
  • Viking Global Investors
  • Viome
  • Virginia Commonwealth University
  • Virtue Group
  • Wacker Biotech
  • Walk-in-Lab
  • Washington Research Foundation
  • Washington University School of Medicine
  • WeGene
  • Wellington Partners
  • Wellmicro
  • Winclove Probiotics
  • Wing Venture Capital
  • WiSEED
  • Xbiome
  • Xycrobe Therapeutics
  • YSOPIA Bioscience
  • Zola Global Investors

Methodology

 

 

Loading
LOADING...